Insider Shareholders with Direct Ownership of Biomarin Pharmaceutical Inc (BMRN)
This section provides a comprehensive overview of the insiders with direct ownership of Biomarin Pharmaceutical Inc (BMRN). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
BIOMARIN PHARMACEUTICAL INC Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Jean Jacques Bienaime
Director |
1,107,475 | 926,535 | 473,792 $29.2 Million | 134 |
May 20, 2024
Reduced 0.25%
|
|
Henry J Fuchs
President, Worldwide R&D |
241,653 | 160,256 | 185,074 $11.4 Million | 21 |
Sep 13, 2024
Reduced 6.14%
|
|
Alexander Hardy
Chief Executive Officer |
148,451 | 14,295 | 134,156 $8.28 Million | 4 |
Nov 29, 2024
Reduced 9.63%
|
|
Richard A Meier
Director |
59,970 | 23,534 | 120,776 $7.46 Million | 13 |
Jun 03, 2024
Reduced 4.32%
|
|
Elaine J Heron
Director |
56,057 | 10,305 | 97,720 $6.03 Million | 10 |
Jun 03, 2024
Reduced 4.09%
|
|
Brian Mueller
EVP, Chief Financial Officer |
144,585 | 103,093 | 71,571 $4.42 Million | 41 |
Jun 28, 2024
Reduced 0.81%
|
|
Charles Greg Guyer
EVP, Chief Technical Officer |
90,073 | 56,697 | 68,909 $4.25 Million | 22 |
Nov 12, 2024
Reduced 7.11%
|
|
Jeffrey Robert Ajer
EVP, Chief Commercial Officer |
168,452 | 165,087 | 66,767 $4.12 Million | 38 |
May 02, 2024
Reduced 6.97%
|
|
George Eric Davis
EVP, Chief Legal Officer |
237,626 | 247,146 | 56,157 $3.47 Million | 39 |
May 28, 2024
Reduced 4.72%
|
|
David E I Pyott
Director |
19,010 | 0 | 49,750 $3.07 Million | 4 |
May 21, 2024
Added 8.67%
|
|
Michael G Grey
Director |
5,000 | 5,000 | 42,840 $2.64 Million | 2 |
Mar 05, 2021
Reduced 10.45%
|
|
Robert J. Hombach
Director |
19,010 | 0 | 35,220 $2.17 Million | 4 |
May 21, 2024
Added 11.82%
|
|
V Bryan Lawlis
Director |
46,290 | 32,000 | 33,140 $2.05 Million | 13 |
May 23, 2023
Added 11.22%
|
|
Willard H Dere
Director |
19,010 | 0 | 32,300 $1.99 Million | 4 |
May 21, 2024
Added 12.75%
|
|
Dennis Slamon
Director |
24,290 | 15,906 | 31,299 $1.93 Million | 6 |
Mar 18, 2024
Reduced 23.3%
|
|
Gregory R Friberg
EVP, Chief R&D Officer |
29,060 | 0 | 29,060 $1.79 Million | 1 |
Sep 30, 2024
Added 21.31%
|
|
Elizabeth M Anderson
Director |
19,010 | 0 | 27,800 $1.72 Million | 4 |
May 21, 2024
Added 14.51%
|
|
Maykin Ho
Director |
21,360 | 0 | 21,360 $1.32 Million | 5 |
May 21, 2024
Added 18.1%
|
|
Cristin Hubbard
EVP, Chief Commercial Officer |
19,390 | 0 | 19,390 $1.2 Million | 1 |
May 20, 2024
Added 19.51%
|
|
Andrea Acosta
GVP, Chief Accounting Officer |
4,561 | 1,217 | 18,122 $1.12 Million | 5 |
Jul 16, 2021
Reduced 1.55%
|
|
Mark J Alles
Director |
15,095 | 0 | 15,095 $931,814 | 4 |
May 23, 2023
Added 21.73%
|
|
Erin Burkhart
GVP, Chief Accounting Officer |
19,610 | 5,161 | 14,449 $891,936 | 8 |
Aug 13, 2024
Reduced 4.71%
|
|
Athena Countouriotis
Director |
6,900 | 0 | 6,900 $425,937 | 2 |
May 21, 2024
Added 40.62%
|
|
Barbara W. Bodem
Director |
6,900 | 0 | 6,900 $425,937 | 2 |
May 21, 2024
Added 40.62%
|
|
Mark J Enyedy
Director |
6,900 | 0 | 6,900 $425,937 | 2 |
May 21, 2024
Added 40.62%
|